Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

144 results about "Claudin" patented technology

Claudins are a family of proteins which, along with occludin, are the most important components of the tight junctions (zonulae occludentes). Tight junctions establish the paracellular barrier that controls the flow of molecules in the intercellular space between the cells of an epithelium. They have four transmembrane domains, with the N-terminus and the C-terminus in the cytoplasm.

Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

InactiveUS20150132253A1Effectively preventingEffectively treatingHeavy metal active ingredientsOrganic active ingredientsDiseaseCombined Modality Therapy
The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Owner:ASTELLAS PHARMA INC +1

Claudin 18.2-targeting CAR molecule, immune cell modified by Claudin 18.2-targeting CAR molecule and application of Claudin 18.2-targeting CAR molecule

The present invention discloses a nucleic acid construct. The nucleic acid construct is characterized in that the nucleic acid construct has a structure as shown in the formula car-[(IRES)-f]<m>, wherein the IRES is a sequence of an internal ribosome entry site, f encodes a functional protein F, m is 0 or a non-0 natural number, car encodes a CAR, the CAR comprises (a) an extracellular binding domain that specifically recognizes CLDN18.2, (b) a hinge domain, (c) a transmembrane domain, (d) a costimulating intracellular domain, and (e) a signal transduction domain, the extracellular binding domain comprises scFv, and the amino acid sequences and functions of the extracellular binding structural domain are described in the specification. The CAR molecule provided by the invention has excellent safety and effectiveness and shows a very good tumor inhibition effect.
Owner:L&L BIOPHARMA CO LTD

Peptide mimotopes of claudin 18.2 and uses thereof

The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.
Owner:JPT PEPTIDE TECH +1

Application of lactobacillus reuteri in preventing and relieving ulcerative colitis

The invention discloses application of lactobacillus reuteri in preventing and relieving ulcerative colitis, and belongs to the technical field of functional microorganisms. Lactobacillus reuteri CCFM1135 can tolerate the gastrointestinal environment of a human body, significantly reduce the disease activity index during the ulcerative colitis, improve colon mucosal injury, reduce MPO activity, reduce the content of proinflammatory factors TNF-alpha, IL-6 and IFN-gamma in colon, up-regulate the transcription level of colon tight junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, up-regulate the transcription levels of colon antibacterial peptides Reg3g and Reg3b, improve the diversity of intestinal flora, and reduced the relative abundance of acinetobacter in excrement.
Owner:JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products